Portfolio
KeyMed Biosciences(2162.HK)
Macromolecular drug R&D platform, with its focus on oncology and autoimmune diseases
China
InventisBio
Small molecule drug R&D platform, with its focus on oncology and metabolic diseases
China
Micot
Peptide and protein drug R&D platform, with its focus on cardiovascular/cerebrovascular diseases, metabolic diseases, and pain related drugs
China
Vedanta
Bacterial innovative therapy R&D platform, with its focus on intestinal microenvironment
America
4B Technologies
Macromolecular drug R&D platform, with its focus on glaucoma, obesity, premature ovarian failure, ALS and NMO
China
WellGene
Gene therapy R&D platform, with its focus on oncology (oncolytic virus) and non-oncology (neurodegenerative diseases, genetic diseases, and blood diseases)
China
Cellestia
Novel gene transcription factor inhibitor R&D platform, with its focus on oncology
Switzerland
Angiex
Antibody-based therapeutics R&D platform, with its focus on TM4SF1 (Transmembrane-4 L Six Family member 1)
America
JURA
Innovative third generation CAR-T therapy R&D platform, with its focus on autoimmune diseases
America
Tavotek
Innovative macromolecular biological drug R&D platform, with its focus on treatment for oncology and autoimmune diseases
China
Concord Medical
Private cancer diagnosis/treatment chain hospital group in Beijing, Shanghai, Guangzhou
China
CH Biomedical
Magnetic left ventricular assist device (LVAD) R&D company, has developed the world's smallest full magnetic levitation artificial heart CH-VAD
China